[go: up one dir, main page]

AU2003271548A1 - Use of skca channel blocking drugs for combating parkinson's disease - Google Patents

Use of skca channel blocking drugs for combating parkinson's disease

Info

Publication number
AU2003271548A1
AU2003271548A1 AU2003271548A AU2003271548A AU2003271548A1 AU 2003271548 A1 AU2003271548 A1 AU 2003271548A1 AU 2003271548 A AU2003271548 A AU 2003271548A AU 2003271548 A AU2003271548 A AU 2003271548A AU 2003271548 A1 AU2003271548 A1 AU 2003271548A1
Authority
AU
Australia
Prior art keywords
disease
channel blocking
blocking drugs
combating
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271548A
Inventor
Bo Skaaning Jensen
Karin Sandager Nielsen
Lene Teuber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2003271548A1 publication Critical patent/AU2003271548A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003271548A 2002-10-13 2003-10-09 Use of skca channel blocking drugs for combating parkinson's disease Abandoned AU2003271548A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201552 2002-10-13
DKPA200201552 2002-10-13
PCT/DK2003/000678 WO2004035056A1 (en) 2002-10-13 2003-10-09 Use of skca channel blocking drugs for combating parkinson's disease

Publications (1)

Publication Number Publication Date
AU2003271548A1 true AU2003271548A1 (en) 2004-05-04

Family

ID=32103844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271548A Abandoned AU2003271548A1 (en) 2002-10-13 2003-10-09 Use of skca channel blocking drugs for combating parkinson's disease

Country Status (2)

Country Link
AU (1) AU2003271548A1 (en)
WO (1) WO2004035056A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511744A4 (en) 2002-05-13 2009-10-21 Icagen Inc Bis-benzimidazoles and related compounds as potassium channel modulators
MX2007001325A (en) 2004-08-05 2008-03-13 Neurosearch As 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels.
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2010015037A1 (en) * 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044853C (en) * 1990-07-19 2004-11-09 Susan A. Greenfield Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
DK154092D0 (en) * 1992-12-23 1992-12-23 Neurosearch As IMIDAZOLE COMPOUNDS, THEIR PREPARATION AND USE
GB9612829D0 (en) * 1996-06-19 1996-08-21 Univ London Potassium channel blockers
US5760230A (en) * 1996-10-11 1998-06-02 Bayer Aktiengesellschaft 4, 4'-bridged bis-2, 4-diaminoquinazolines
US5874438A (en) * 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
US5739127A (en) * 1996-11-08 1998-04-14 Bayer Aktiengesellschaft 2,4'-bridged bis-2,4-diaminoquinazolines
DE60005517T2 (en) * 1999-06-29 2004-07-01 Neurosearch A/S POTASS CHANNEL BLOCKING AGENTS
JP2005518346A (en) * 2001-11-07 2005-06-23 メディカル リサーチ カウンセル Regulation of dopaminergic neurons
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels

Also Published As

Publication number Publication date
WO2004035056A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
AU2003214191A1 (en) Implantable medical device stream processor
AU2002334579A1 (en) Medical device containing light-protected therapeutic agent
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
AU2003272590A1 (en) Method for ophtalmic administration of medicament
AU2003295614A1 (en) Delivery of pharmaceutical agents via the human insulin receptor
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2002342050A1 (en) Anesthesia drug monitor
AU2003223005A1 (en) Application device for topical administration of pharmaceutical agents
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003243439A1 (en) Medical device for intra-lumenal delivery of pharmaceutical agents
EP1583506A3 (en) Eye-drop vaccine containing copolymer 1 for therapeutic immunization
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
AU2003249105A1 (en) Processes for the preparation of oral dosage formulations of modafinil
AU2003228464A1 (en) Apparatus for treatment of meniere's disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
AU5729099A (en) Use of cyclopentabenzofuran-derivatives for combating nf-KappaB-dependent diseases
AU2003271548A1 (en) Use of skca channel blocking drugs for combating parkinson's disease
AU2002251541A1 (en) Apparatus and assembly for administering antimicrobial agent
AU2003235635A1 (en) Diagnostic and therapeutic use of the voltage-gated ion channel scn2a for neurodegenerative diseases
AU2003247001A1 (en) Processes for the preparation of oral dosage formulations of modafinil
AU2003277298A1 (en) Pharmaceutical compositions for treatment of parkinson's disease
AU2001260281A1 (en) Medicament for combating respiratory depression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase